Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA scrutiny cause shareholders to lash out at Spectranetics

This article was originally published in Clinica

Executive Summary

Medical laser specialist Spectranetics has been hit with several securities class action lawsuits after its share price lost more than half its value overnight on news that the company was being investigated by the US FDA and US Immigration and Customs Enforcement. The inquiry, launched earlier this month, relates to alleged improper business practices by the Colorado Springs, Colorado-based company, specifically the promotion, use, testing, sales and marketing of certain Spectranetics products (see Clinica 1323, p 23). The firm has also been requested by the Denver office of the Securities and Exchange Commission to provide certain unspecified documents. It said it intends to co-operate fully with the investigation. Spectranetics' shares have been trading in the $5.63-3.98 range since September 3 – the stock was valued at around $9 per share around August.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel